Application of flueggemine B in preparation of medicine for treating pulmonary fibrosis

By using baicalein B to improve epithelial phenotype and inhibit myofibroblast activation, drugs in various dosage forms have been prepared, overcoming the limitations of existing pulmonary fibrosis treatments, significantly improving lung function and tissue structure, and increasing survival rates.

CN121818633APending Publication Date: 2026-04-10SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
0 Cites 0 Cited by

Patent Information

Application Number
CN202610116475.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-28
Publication Date
2026-04-10

AI Technical Summary

Technical Problem

Existing drugs for pulmonary fibrosis treatment have limited efficacy, limited applicable populations, significant adverse reactions, limited clinical treatment options, a five-year survival rate of less than 30%, and a lack of effective drug treatment options.

Method used

Using bleomycin B or its pharmaceutically acceptable salts, it improves epithelial phenotype and inhibits abnormal activation of myofibroblasts. It is prepared into tablets, capsules, granules, oral liquids, injections, lyophilized powder for injection, and inhalation aerosols, and administered orally, intravenously, subcutaneously, intratracheally, or via nebulization to intervene in a mouse model of bleomycin-induced pulmonary fibrosis.

Benefits of technology

It significantly improves lung function, reduces collagen deposition, inhibits myofibroblast activation, improves lung tissue structure, alleviates the degree of pulmonary fibrosis, and improves quality of life.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of flueggeine B or pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. The chemical structure of the flueggeine B is shown as a formula (I). The flueggemine B shows an improvement effect in a bleomycin-induced pulmonary fibrosis mouse model, improves the weight and lung function parameters of a mouse, relieves the degree of pulmonary fibrosis, has an inhibition effect on lung tissue collagen deposition, can also effectively improve the phenotype of pulmonary epithelial cells and inhibit abnormal activation of myofibroblasts, and can be used for treating pulmonary fibrosis. Therefore, the traditional Chinese medicine composition has a remarkable relieving effect on bleomycin-induced pulmonary fibrosis.
Need to check novelty before this filing date? Find Prior Art